These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32886634)

  • 21. Compounding botanicals: a legal perspective.
    Valentino JG; Bormel FG
    J Am Pharm Assoc (Wash); 1999; 39(4):537-44. PubMed ID: 10467820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Current Landscape of Veterinary Compounding in the Pharmacy Setting.
    Gochenauer AE; Holmes ER; Barber KE; Forsythe LR
    Int J Pharm Compd; 2019; 23(5):422-427. PubMed ID: 31513542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. History of sterile compounding in U.S. hospitals: learning from the tragic lessons of the past.
    Myers CE
    Am J Health Syst Pharm; 2013 Aug; 70(16):1414-27. PubMed ID: 23903480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compounding in Ukraine.
    Zdoryk OA; Georgiyants VA; Gryzodub OI; Schnatz R
    Int J Pharm Compd; 2013; 17(2):124-7. PubMed ID: 23696172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe.
    Minghetti P; Pantano D; Gennari CG; Casiraghi A
    Health Policy; 2014 Sep; 117(3):328-33. PubMed ID: 25110297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. U.S. Compounding Pharmacy-Related Outbreaks, 2001-2013: Public Health and Patient Safety Lessons Learned.
    Shehab N; Brown MN; Kallen AJ; Perz JF
    J Patient Saf; 2018 Sep; 14(3):164-173. PubMed ID: 26001553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basics of compounding: repackaging, part 2.
    Allen LV
    Int J Pharm Compd; 2013; 17(2):136-40. PubMed ID: 23696175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Compounding Pharmacists During Drug Shortages.
    Ofei K
    Int J Pharm Compd; 2022; 26(4):298-301. PubMed ID: 35820135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists.
    Quertermous J; Desai S; Harper J; Lebwohl M; Torres A; Kircik LH
    J Drugs Dermatol; 2018 Jul; 17(7):s17-s22. PubMed ID: 30005109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability in compounding of oral liquids for pediatric patients: a patient safety concern.
    Rood JM; Engels MJ; Ciarkowski SL; Wagenknecht LD; Dickinson CJ; Stevenson JG
    J Am Pharm Assoc (2003); 2014; 54(4):383-9. PubMed ID: 25063260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List).
    Int J Pharm Compd; 2016; 20(6):457-458. PubMed ID: 28339383
    [No Abstract]   [Full Text] [Related]  

  • 34. Leveraging a multidisciplinary oversight committee to ensure USP <797> and <800> compliance at a Veterans Affairs health system.
    Wrzesniewski CE; Park HK
    Am J Health Syst Pharm; 2022 Feb; 79(4):276-282. PubMed ID: 34724546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When government agencies turn to unregulated drug sources: Implications for the drug supply chain and public health are grave.
    Yadav P; Weintraub RL; Stergachis A
    J Am Pharm Assoc (2003); 2018; 58(5):477-480. PubMed ID: 30077566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.
    AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S
    BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies.
    Kastango ES
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):38S-39S. PubMed ID: 22275322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of United States pharmacopeia chapter 795 and american society of health-system pharmacists guidelines for nonsterile compounding.
    McElhiney LF
    Int J Pharm Compd; 2009; 13(6):525-30. PubMed ID: 23965326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Extent of Extemporaneous Preparation and Regulatory Framework of Extemporaneous Compounding in Latvia.
    Kiseļova O; Mauriņa B; Šidlovska V; Zvejnieks J
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31454896
    [No Abstract]   [Full Text] [Related]  

  • 40. Compounding interest: a tragedy caused by contaminated steroids turned the spotlight on compounding pharmacies.
    Hinkley KN
    State Legis; 2013 Jun; 39(6):22-3. PubMed ID: 23805443
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.